Will Downtrend Continue In Arch Coal Inc (ACI), Vringo Inc. (VRNG), And Ibio Inc (IBIO)?
New York, NY – GDP INSIDER – 01/05/2014.
Public comments are being sought in Montana over Arch Coal Inc (NYSE:ACI)’s mine application. The Department of Environmental Quality in Montana has 120 days to look into the application of Arch Coal concerning the building of the Otter Creek mine. Therefore, the public comments are required to come in advance to allow for full consideration.
In 2013, Montana turned down Arch Coal Inc (NYSE:ACI)’s Otter Creek mine application, forcing the company to submit a revised document in 2014. The Department of Environmental Quality could still ask for more documentation from the company or clear the application.
Still, even after clearance, it is expected to take Arch Coal Inc (NYSE:ACI) some more years to develop the mine. The stringent regulatory hurdles in Montana are emblematic of the changing operation landscape for coal companies.
Intellectual property monetization company, Vringo, Inc. (NASDAQ:VRNG), successfully defended its technology in the U.K. against Chinese hardware maker ZTE. As such, a court in the U.K. recently asked ZTE to make a payment of about $938,000 to Vringo to settle the latter’s legal costs related to a patent suit.
Vringo, Inc. (NASDAQ:VRNG) challenged ZTE’s use of 3G/4G hardware infrastructure. It claimed that the use of the technology in the U.K. violated its European patent No. 1,212,919.
The win against ZTE in the U.K. comes as a reprieve to Vringo, Inc. (NASDAQ:VRNG). The company recently received an unfavorable decision against Google Inc (NASDAQ:GOOGL) in a patent dispute.
Ibio Inc (NYSEMKT:IBIO) recently updated on the progress of its drug candidate IBIO-CFB03, especially regarding the potential of the compound in combating fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). According to the company, preclinical trials of the compound showed that it is effective in treating fibrotic diseases. As such, the results justify further development of the compound to address unmet medical needs.
Therefore, Ibio Inc (NYSEMKT:IBIO) is determined to invest in the Phase 1 trial of the compound, which will further assess its efficacy and safety in participating patients.
Ibio Inc (NYSEMKT:IBIO) boasts a proprietary drug development platform known as iBioLaunch.
UltimateStockAlerts.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.
UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
Disclosure: UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.